Xtant Medical

Investors

Corporate Profile

Xtant Medical Holdings, Inc. (NYSE MKT: XTNT) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries.


Stock Quote
XTNT (Common Stock)
Price$6.19
Change (%) + 0.33 (5.63%)
Volume40,605
Data as of 06/22/18 6:30 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart


Recent News
DateTitle 
06/19/18Xtant Medical Holdings, Inc. Announces Expiration of Rights Offering
BELGRADE, MT, June 19, 2018 (GLOBE NEWSWIRE) -- XtantTM Medical Holdings, Inc. (NYSE American: XTNT) announces that the subscription period for its previously announced rights offering (the “Offering”) of shares of the Company’s common stock at a subscription price of $7.20 per share expired on June 18, 2018, and these rights are no longer exercisable. Based on the review of preliminary results provided by the Company’s subscription agent, Corporate Stock Transfer, Inc., Xtant Medical expects... 
05/21/18Xtant Medical Receives FDA 510(K) Clearance for InTice™-C Porous Titanium Cervical Interbody System
BELGRADE, MT / ACCESSWIRE / May 21, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, announces U.S. Food and Drug Administration (FDA) 510(k) clearance for InTice™-C Porous Titanium Cervical Interbody System.InTice-C is designed using OsteoSync Ti, a best-in-class, cost-effective, highly porous titanium scaffold material for improved implant fixation. The material more closely resembles the bioscaffold o... 
05/08/18Xtant Medical Announces First Quarter 2018 Financial Results
BELGRADE, MT / ACCESSWIRE / May 8, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today reported financial and operating results for the first quarter of 2018.First Quarter 2018 Financial Highlights and Recent Accomplishments: Revenue for the first quarter 2018 was $17.9 million, down from $22.1 million for the first quarter of 2017 Gross Margin for the first quarter 2018 was 68.2%, compared to... 
05/02/18Xtant Medical to Issue First Quarter 2018 Results on May 8th, 2018
BELGRADE, MT / ACCESSWIRE / May 2, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the quarter ended March 31, 2018, after the close of the financial markets on Tuesday, May 8, 2018.An accompanying conference call will be conducted by Carl O'Connell, Chief Executive Officer and President, and Laura Kendall, Interim Chief Financial Officer, t... 
More


Upcoming Events
There are currently no events scheduled.
More

Receive Email Alerts
Sign up to receive email alerts whenever Xtant Medical Holdings Inc posts new information to the site. Just enter your email address and click Submit.